Lyu N, et al. - Experts comparatively assessed the overall survival (OS) and disease progression free survival (PFS) in patients with advanced hepatocellular carcinoma (Ad-HCC) who were undergoing hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment vs sorafenib. Data revealed that the median PFS and OS in HAIF group were considerably longer than those in sorafenib group. The inference drawn was that HAIF therapy possibly displayed a potential benefit of survival in patients with Ad-HCC